Cardiovascular Outcomes With Empagliflozin and Dapagliflozin in Patients Without Diabetes-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cardiovascular Outcomes With Empagliflozin and Dapagliflozin in Patients Without Diabetes

Published:2024-05 Issue: Volume:218 Page:24-31
ISSN:0002-9149
Container-title:The American Journal of Cardiology
language:en
Short-container-title:The American Journal of Cardiology

Author:

Singh Sahib^ORCID,Garg Aakash,Tantry Udaya S,Bliden Kevin,Gurbel Paul A.,Gulati Martha^ORCID

Publisher

Elsevier BV

Reference28 articles.

1. Heart disease and stroke statistics-2023 update: a report from the American Heart Association;Tsao;Circulation,2023

2. SGLT-2 inhibitors: a new mechanism for glycemic control;Chao;Clin Diabetes,2014

3. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023;ElSayed;Diabetes Care,2023

4. Effect of SGLT2 inhibitors on cardiovascular outcomes across various patient populations;Usman;J Am Coll Cardiol,2023

5. Efficacy and safety of the sodium-glucose co-transporter-2 inhibitor empagliflozin in elderly Japanese adults (≥65 years) with type 2 diabetes: a randomized, double-blind, placebo-controlled, 52-week clinical trial (EMPA-ELDERLY);Yabe;Diabetes Obes Metab,2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP